Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8014455 | 0.89 | — | — | |
| SCHEMBL6838867 | 0.82 | CA2 (0.32) | — | |
| SCHEMBL223234 | 0.81 | NUDT1 (0.33) | — | |
| SCHEMBL8459699 | 0.81 | — | — | |
| SCHEMBL16359166 | 0.77 | — | — | |
| SCHEMBL18942730 | 0.77 | MEN1 (0.38) | — | |
| SCHEMBL533932 | 0.77 | — | — | |
| SCHEMBL6050013 | 0.77 | ALDH1A1 (0.33) | ALDH1A1TP53CYP3A4MAPK1SMN1; SMN2 | |
| SCHEMBL22748890 | 0.77 | — | — | |
| SCHEMBL19437668 | 0.77 | GBA2 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724417-A1 | TRICINE AND CITRIC ACID-BASED CATIONIC LIPIDS WITH AROMATIC HEAD GROUPS | Sanofi (FR) | 2026-04-15 | — | — | EP | disclosed |
| US-12545636-B2 | Acyclic lipids and methods of use thereof | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2026-02-10 | — | — | US | disclosed |
| EP-4655402-A1 | NUCLEIC ACID VACCINES FOR VARICELLA-ZOSTER VIRUS (VZV) | Providence Therapeutics Holdings Inc. (CA) | 2025-12-03 | — | — | EP | disclosed |
| US-20250319190-A1 | APOE LIPOPROTEIN SYSTEMS | KISBEE THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250313525-A1 | CONSTRAINED LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MAN INC (US) | 2025-10-09 | — | — | US | disclosed |
| US-20250154102-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MAN INC (US) | 2025-05-15 | — | — | US | disclosed |
| EP-3733844-B1 | COMPOSITION FOR MODIFYING TARGET GENE | UNIV KYOTO (JP) | 2025-04-02 | — | — | EP | disclosed |
| EP-4522646-A2 | APOE LIPOPROTEIN SYSTEMS | Kisbee Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| US-20250073164-A1 | IONIZABLE DISULFIDE LIPIDS AND LIPID NANOPARTICLES DERIVED THEREFROM | PROVIDENCE THERAPEUTICS HOLDINGS INC. (CA) | 2025-03-06 | — | — | US | disclosed |
| US-12215068-B2 | Constrained lipids and methods of use thereof | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2025-02-04 | — | — | US | disclosed |
| EP-3733844-A1 | COMPOSITION FOR MODIFYING TARGET GENE | Kyoto University (JP) | 2020-11-04 | — | — | EP | disclosed |
| US-20200331841-A1 | CATIONIC LIPIDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-10-22 | — | — | US | disclosed |
| CN-111527204-A | Composition for target gene modification | 国立大学法人京都大学 | 2020-08-11 | — | — | CN | disclosed |
| CN-111511713-A | Cationic lipid | 武田药品工业株式会社 | 2020-08-07 | — | — | CN | disclosed |
| EP-3178807-B1 | CATIONIC LIPID | TAKEDA PHARMACEUTICALS CO (JP) | 2020-04-29 | — | — | EP | disclosed |
| US-10252974-B2 | Cationic lipid | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-04-09 | — | — | US | disclosed |
| US-20170197903-A1 | CATIONIC LIPID | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-07-13 | — | — | US | disclosed |
| EP-3178807-A1 | CATIONIC LIPID | Takeda Pharmaceutical Company Limited (JP) | 2017-06-14 | — | — | EP | disclosed |
| US-6469065-B1 | COMPOUND THAT DONATES, TRANSFERS OR RELEASES NITRIC OXIDE, ELEVATES ENDOGENOUS LEVELS OF NITRIC OXIDE | NITROMED, INC. | 2002-10-22 | — | — | US | disclosed |
| US-20020143007-A1 | Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use | GARVEY DAVID S (US) | 2002-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250313525-A1 | CONSTRAINED LIPIDS AND METHODS OF USE THEREOF | SGMS1, SGMS2, LNPEP | ALDH1A1 4876/4885TP53 1522/4885CYP3A4 4849/4885 |
| US-20170197903-A1 | CATIONIC LIPID | NPC1L1, SOAT2, CETP | ALDH1A1 2010/4885TP53 1996/4885CYP3A4 3645/4885 |
| US-20250319190-A1 | APOE LIPOPROTEIN SYSTEMS | APOB, APOL1, LDLR | ALDH1A1 3260/4885TP53 1486/4885CYP3A4 2354/4885 |
| US-20250073164-A1 | IONIZABLE DISULFIDE LIPIDS AND LIPID NANOPARTICLES DERIVED THEREFROM | SGMS1, SGMS2, ABCB4 | ALDH1A1 3146/4885TP53 439/4885CYP3A4 4543/4885 |
| US-12545636-B2 | Acyclic lipids and methods of use thereof | PLTP, LNPEP, PCTP | ALDH1A1 4885/4885TP53 2065/4885CYP3A4 4852/4885 |
| US-20020143007-A1 | Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use | ADRB1, ADRB3, ADRA1D | ALDH1A1 610/4885TP53 2595/4885CYP3A4 504/4885 |
| US-12215068-B2 | Constrained lipids and methods of use thereof | SGMS1, SGMS2, LNPEP | ALDH1A1 4876/4885TP53 1522/4885CYP3A4 4849/4885 |
| US-20250154102-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | SGMS1, SGMS2, LNPEP | ALDH1A1 4882/4885TP53 1361/4885CYP3A4 4863/4885 |
| US-10252974-B2 | Cationic lipid | NPC1L1, SOAT2, CETP | ALDH1A1 2010/4885TP53 1996/4885CYP3A4 3645/4885 |
| US-20200331841-A1 | CATIONIC LIPIDS | ELOVL5, LPCAT3, ELOVL3 | ALDH1A1 3506/4885TP53 3642/4885CYP3A4 4070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.